MEDP vs. NVO: Medpace vs. Novo Nordisk Stock Comparison

Company Profile

Medpace (MEDP) and Novo Nordisk (NVO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while NVO is classified in Pharmaceuticals.

Medpace (MEDP) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Novo Nordisk (NVO) is heavily traded at around 12.11M shares per day, whereas Medpace (MEDP) sees a more moderate 258.39K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Novo Nordisk (NVO) at 58.38% also sits in the top quartile.

Both Medpace (MEDP) at 18.24% and Novo Nordisk (NVO) at 33.92% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Medpace (MEDP) at 23.12% and Novo Nordisk (NVO) at 40.05% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Medpace (MEDP) at 19.97% and Novo Nordisk (NVO) at 6.43% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Medpace (MEDP) at 20.98% and Novo Nordisk (NVO) at 1.77% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Medpace (MEDP) at 0.83 and Novo Nordisk (NVO) at 0.85 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Medpace (MEDP) at 0.29 and Novo Nordisk (NVO) at 0.62 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while Medpace (MEDP) at 36.26 is closer to its industry’s usual earnings multiple — a discount for NVO, though growth and earnings durability still matter.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Medpace (MEDP) at 6.44 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

Novo Nordisk (NVO) at 5.43 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.

Valuation Metrics